RESPONSIBILITY AFTER THE APPARENT END: ‘FOLLOWING-UP’ IN CLINICAL ETHICS CONSULTATION
✍ Scribed by STUART G. FINDER; MARK J. BLITON
- Book ID
- 110974566
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 137 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0269-9702
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Objective: To evaluate the 5‐year clinical outcomes of patients treated with the Endeavor zotarolimus‐eluting stent (ZES) in the ENDEAVOR I first‐in‐human study. Background: ENDEAVOR I was a prospective, nonrandomized, multicenter study of the Endeavor ZES in 100 consecutive patients wi
for the Brazilian Wilms' Tumor Study Group$ Background. To verify the adequacy of a simplified chemotherapeutic regimen for the treatment of Wilms' tumor (WT), the authors conducted a clinical trial to compare the standard fractionated dose (15 mcg/kg x 5 days) of dactinomycin (AMD) with a single do